Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Cancer Vaccines01:30

Cancer Vaccines

310
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
310

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.

JTO clinical and research reports·2026
Same author

LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli Health Maintenance Organization (HMO).

Expert review of anticancer therapy·2026
Same author

Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung Cancer.

Cancers·2026
Same author

Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies.

Current oncology (Toronto, Ont.)·2026
Same author

Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion.

Advances in therapy·2025
Same author

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Related Experiment Video

Updated: May 20, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

992

Lung Cancer: Targeted Therapy in 2025.

Nicole Bouchard1, Nathalie Daaboul2

  • 1Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.

Current Oncology (Toronto, Ont.)
|March 26, 2025
PubMed
Summary
This summary is machine-generated.

Targeted therapies for non-small cell lung cancer (NSCLC) have advanced significantly. This review covers actionable genomic alterations (AGAs) like EGFR mutations and their targeted treatments, including adjuvant and stage III options.

Keywords:
lung cancermolecular testingtargeted therapy

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.5K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.0K

Related Experiment Videos

Last Updated: May 20, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

992
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.5K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.0K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • The landscape of lung cancer treatment has been revolutionized by the identification of actionable genomic alterations (AGAs).
  • Non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, frequently harbors these AGAs.
  • Understanding these alterations is crucial for personalized treatment strategies.

Purpose of the Study:

  • To provide a comprehensive review of the current state-of-the-art treatments for specific AGAs in NSCLC.
  • To discuss the clinical implications and toxicities of targeted therapies for these alterations.
  • To explore treatment options beyond the metastatic setting, including adjuvant and stage III therapies.

Main Methods:

  • Literature review of current research and clinical guidelines on actionable genomic alterations in NSCLC.
  • Focus on targeted therapies for EGFR, ALK, ROS1, BRAF V600E, METex14, RET, KRAS G12C, ERBB2 (HER2), and NTRK alterations.
  • Inclusion of data on treatment efficacy, toxicity profiles, and application in different disease stages.

Main Results:

  • Targeted therapies have demonstrated significant efficacy in NSCLC patients with specific AGAs.
  • Established treatments exist for EGFR mutations, ALK and ROS1 fusions, BRAF V600E, METex14, RET, KRAS G12C, ERBB2, and NTRK fusions.
  • Adjuvant and stage III treatment strategies are emerging for certain AGAs, notably EGFR mutations and ALK fusions.

Conclusions:

  • Actionable genomic alterations are key drivers in NSCLC, necessitating molecular profiling for optimal treatment selection.
  • Targeted therapies offer improved outcomes for patients with specific AGAs across various disease stages.
  • Ongoing research continues to expand therapeutic options and refine treatment approaches for NSCLC.